

**KENTURN NANO. TEC. CO., LTD.****Financial Statements****With Independent Auditors' Review Report  
For the Three Months Ended March 31, 2024 and 2023**

Address: No.16, East 7 Rd. Chang-Bin Industrial Park, Changhua, Taiwan (R.O.C.)  
Telephone: 886-4-791-0271

The independent auditors' review report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and financial statements, the Chinese version shall prevail.

## Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Balance Sheets	4
5. Statements of Comprehensive Income	5
6. Statements of Changes in Equity	6
7. Statements of Cash Flows	7
8. Notes to the Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the financial statements	8
(3) New standards, amendments and interpretations adopted	8~9
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~29
(7) Related-party transactions	29
(8) Pledged assets	29
(9) Commitments and contingencies	30
(10) Losses due to major disasters	30
(11) Subsequent Events	30
(12) Other	30
(13) Other disclosures	
(a) Information on significant transactions	30~31
(b) Information on investees	31
(c) Information on investment in Mainland China	31
(d) Major shareholders	31
(14) Segment information	31



安侯建業聯合會計師事務所  
KPMG

台中市407544西屯區文心路二段201號7樓  
7F, No.201, Sec.2, Wenxin Road,  
Taichung City 407059, Taiwan (R.O.C.)

電話 Tel +886 4 2415 9168  
傳真 Fax +886 4 2259 0196  
網址 Web kpmg.com/tw

## Independent Auditors' Review Report

To the Board of Directors of Kenturn Nano. Tec. Co., Ltd.:

### Introduction

We have reviewed the accompanying balance sheets of Kenturn Nano. Tec. Co., Ltd. as of March 31, 2024 and 2023, and the related statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2024 and 2023, and notes to the financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the financial statements based on our reviews.

### Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying financial statements do not present fairly, in all material respects, the financial position of Kenturn Nano. Tec. Co., Ltd. as of March 31, 2024 and 2023, and of its financial performance and its cash flows for the three months ended March 31, 2024 and 2023 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors' review report are Chen, Cheng-Hsueh and Chen, Yen-Hui.

KPMG

Taipei, Taiwan (Republic of China)  
May 7, 2024

### Notes to Readers

The accompanying financial statements are intended only to present the statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and financial statements, the Chinese version shall prevail.

(English Translation of Financial Statements Originally Issued in Chinese)  
KENTURN NANO. TEC. CO., LTD.

Balance Sheets

March 31, 2024, December 31, 2023, and March 31, 2023

(Expressed in Thousands of New Taiwan Dollars)

Assets		March 31, 2024		December 31, 2023		March 31, 2023		Liabilities and Equity		March 31, 2024		December 31, 2023		March 31, 2023	
		Amount	%	Amount	%	Amount	%			Amount	%	Amount	%	Amount	%
<b>Current assets:</b>								<b>Current liabilities:</b>							
1100	Cash and cash equivalents(note 6(a))	\$ 650,145	27	545,980	23	526,724	23	2100	Short-term borrowings(notes 6(i) and 8)	\$ 50,000	2	50,000	2	125,600	6
1136	Current financial assets at amortized cost(note 6(b))	19,200	1	79,833	4	49,816	2	2130	Current contract liabilities(note 6(r))	25,043	1	36,619	2	75,185	3
1150	Notes receivable(note 6(c))	3,195	-	6,474	-	5,051	-	2150	Notes payable	181,857	7	215,761	9	107,407	5
1170	Accounts receivable(note 6(c))	158,961	7	204,138	9	100,970	4	2170	Accounts payable	94,084	4	52,417	2	75,055	3
1310	Inventories(note 6(d))	298,560	12	252,077	10	280,031	12	2200	Other payables(note 6(j))	64,798	3	79,604	3	50,696	2
1470	Other current assets(notes 6(h) and 8)	10,218	-	5,070	-	39,130	2	2230	Current income tax liabilities	62,932	2	49,221	2	35,789	2
		<u>1,140,279</u>	<u>47</u>	<u>1,093,572</u>	<u>46</u>	<u>1,001,722</u>	<u>43</u>	2280	Current lease liabilities(note 6(m))	949	-	396	-	-	-
<b>Non-current assets:</b>								2300	Other current liabilities(note 6(k))	18,317	1	18,146	1	1,909	-
1600	Property, plant and equipment(notes 6(e) and 8)	1,266,949	52	1,282,864	53	1,312,848	56	2322	Long-term borrowings, current portion(notes 6(l) and 8)	<u>64,829</u>	<u>3</u>	<u>67,244</u>	<u>3</u>	<u>78,867</u>	<u>3</u>
1755	Right-of-use assets(note 6(g))	2,631	-	1,100	-	-	-			<u>562,809</u>	<u>23</u>	<u>569,408</u>	<u>24</u>	<u>550,508</u>	<u>24</u>
1780	Intangible assets(note 6(f))	5,613	-	6,076	-	6	-	<b>Non-Current liabilities:</b>							
1840	Deferred income tax assets	27,773	1	27,773	1	22,469	1	2540	Long-term borrowings(notes 6(l) and 8)	543,984	22	558,973	23	609,501	26
1900	Other non-current assets(note 6(h))	<u>2,590</u>	<u>-</u>	<u>10</u>	<u>-</u>	<u>-</u>	<u>-</u>	2570	Deferred income tax liabilities	2,859	-	2,859	-	4,290	-
		1,305,556	53	1,317,823	54	1,335,323	57	2580	Non-current lease liabilities(note 6(m))	1,527	-	641	-	-	-
								2640	Net defined benefit liability, non-current	<u>18,852</u>	<u>1</u>	<u>18,903</u>	<u>1</u>	<u>18,354</u>	<u>1</u>
										<u>567,222</u>	<u>23</u>	<u>581,376</u>	<u>24</u>	<u>632,145</u>	<u>27</u>
									<b>Total liabilities</b>	<u>1,130,031</u>	<u>46</u>	<u>1,150,784</u>	<u>48</u>	<u>1,182,653</u>	<u>51</u>
									<b>Equity(note 6(p)):</b>						
								3100	Ordinary shares	585,216	24	585,216	24	585,216	25
								3200	Capital surplus	210,536	9	210,536	9	210,536	9
								3300	Retained earnings	<u>520,052</u>	<u>21</u>	<u>464,859</u>	<u>19</u>	<u>358,640</u>	<u>15</u>
									<b>Total equity</b>	<u>1,315,804</u>	<u>54</u>	<u>1,260,611</u>	<u>52</u>	<u>1,154,392</u>	<u>49</u>
<b>Total assets</b>		<u>\$ 2,445,835</u>	<u>100</u>	<u>2,411,395</u>	<u>100</u>	<u>2,337,045</u>	<u>100</u>	<b>Total liabilities and equity</b>		<u>\$ 2,445,835</u>	<u>100</u>	<u>2,411,395</u>	<u>100</u>	<u>2,337,045</u>	<u>100</u>

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)  
**KENTURN NANO. TEC. CO., LTD.**

**Statements of Comprehensive Income**

**For the three months ended March 31, 2024 and 2023**

(Expressed in Thousands of New Taiwan Dollars , Except for Earnings Per Common Share)

		<b>For the three months ended March 31</b>			
		<b>2024</b>		<b>2023</b>	
		<b>Amount</b>	<b>%</b>	<b>Amount</b>	<b>%</b>
4000	<b>Operating revenue(note 6(r))</b>	\$ 276,600	100	234,467	100
5000	<b>Operating costs(notes 6(d), (n) and (s))</b>	<u>184,954</u>	<u>67</u>	<u>186,542</u>	<u>80</u>
	<b>Gross profit from operations</b>	<u>91,646</u>	<u>33</u>	<u>47,925</u>	<u>20</u>
	<b>Operating expenses(note 6(m), (n) and (s))</b>				
6100	Selling expenses	7,327	2	6,876	3
6200	Administrative expenses	22,565	8	18,531	8
6300	Research and development expenses	4,884	2	4,128	2
6450	Expected credit (gains) losses(note 6(c))	<u>(1,131)</u>	<u>-</u>	<u>3,415</u>	<u>1</u>
		<u>33,645</u>	<u>12</u>	<u>32,950</u>	<u>14</u>
	<b>Net operating income</b>	<u>58,001</u>	<u>21</u>	<u>14,975</u>	<u>6</u>
	<b>Non-operating income and expenses(note 6(t))</b>				
7100	Interest income	899	-	511	-
7010	Other income	137	-	305	-
7020	Other gains and losses	12,958	5	2,957	1
7050	Finance costs(note 6(m))	<u>(3,004)</u>	<u>(1)</u>	<u>(3,494)</u>	<u>(1)</u>
		<u>10,990</u>	<u>4</u>	<u>279</u>	<u>-</u>
7900	<b>Profit before income tax</b>	68,991	25	15,254	6
7950	Less: Income tax expenses(note 6(o))	<u>13,798</u>	<u>5</u>	<u>3,051</u>	<u>1</u>
8200	<b>Profit</b>	<u>55,193</u>	<u>20</u>	<u>12,203</u>	<u>5</u>
8300	<b>Other comprehensive income</b>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>
8500	<b>Total comprehensive income</b>	<u>\$ 55,193</u>	<u>20</u>	<u>12,203</u>	<u>5</u>
	<b>Earnings per share (NT dollars) (note 6(q))</b>				
9750	<b>Basic earnings per share</b>	<u>\$ 0.94</u>		<u>0.21</u>	
9850	<b>Diluted earnings per share</b>	<u>\$ 0.94</u>		<u>0.21</u>	

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)

**KENTURN NANO. TEC. CO., LTD.**

**Statements of Changes in Equity**

**For the three months ended March 31, 2024 and 2023**

**(Expressed in Thousands of New Taiwan Dollars)**

	Ordinary shares	Capital surplus	Retained earnings		Total	Total equity
			Legal reserve	Unappropriated retained earnings		
<b>Balance at January 1, 2023</b>	\$ 585,216	210,536	80,819	265,618	346,437	1,142,189
Profit for the period	-	-	-	12,203	12,203	12,203
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	12,203	12,203	12,203
<b>Balance at March 31, 2023</b>	<b>\$ 585,216</b>	<b>210,536</b>	<b>80,819</b>	<b>277,821</b>	<b>358,640</b>	<b>1,154,392</b>
<b>Balance at January 1, 2024</b>	\$ 585,216	210,536	91,595	373,264	464,859	1,260,611
Profit for the period	-	-	-	55,193	55,193	55,193
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	55,193	55,193	55,193
<b>Balance at March 31, 2024</b>	<b>\$ 585,216</b>	<b>210,536</b>	<b>91,595</b>	<b>428,457</b>	<b>520,052</b>	<b>1,315,804</b>

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)  
KENTURN NANO. TEC. CO., LTD.

Statements of Cash Flows

For the three months ended March 31, 2024 and 2023

(Expressed in Thousands of New Taiwan Dollars)

	For the three months ended March 31	
	2024	2023
<b>Cash flows from (used in) operating activities:</b>		
Profit before tax	\$ 68,991	15,254
<b>Adjustments:</b>		
<b>Adjustments to reconcile profit (loss):</b>		
Depreciation expense	17,740	16,992
Amortization expense	564	10
Expected credit (gain) loss	(1,131)	3,415
Interest expense	3,004	3,494
Interest income	(899)	(511)
Loss on valuation of inventories	723	8,112
<b>Total adjustments to reconcile profit</b>	<u>20,001</u>	<u>31,512</u>
<b>Changes in operating assets and liabilities:</b>		
<b>Changes in operating assets:</b>		
Decrease in notes receivable	3,279	8,821
Decrease in accounts receivable	46,308	23,916
(Increase) decrease in other receivable	(1,603)	7,542
(Increase) decrease in inventories	(47,206)	10,234
(Increase) decrease in other current assets	(3,545)	530
<b>Total changes in operating assets</b>	<u>(2,767)</u>	<u>51,043</u>
<b>Changes in operating liabilities:</b>		
Decrease in contract liabilities	(11,576)	(164)
Decrease in notes payable	(33,904)	(31,273)
Increase in accounts payable	41,667	43,678
Decrease in other payables	(12,465)	(7,562)
Increase in other current liabilities	171	245
Decrease in net defined benefit liability	(51)	(49)
<b>Total changes in operating liabilities</b>	<u>(16,158)</u>	<u>4,875</u>
<b>Total changes in operating assets and liabilities</b>	<u>(18,925)</u>	<u>55,918</u>
Cash generated from operations	70,067	102,684
Interest received	899	511
Interest paid	(3,014)	(3,514)
Income taxes paid	(87)	(56)
<b>Net cash flows from (used in) operating activities</b>	<u>67,865</u>	<u>99,625</u>
<b>Cash flows from (used in) investing activities:</b>		
Decrease acquisition of financial assets at amortized cost	60,633	426
Acquisition of property, plant and equipment	(4,127)	(11,080)
Acquisition of intangible assets	(101)	-
Decrease in other financial assets	-	260
Increase in prepayments for business facilities	(2,580)	-
<b>Net cash flows from (used in) investing activities</b>	<u>53,825</u>	<u>(10,394)</u>
<b>Cash flows used in financing activities:</b>		
Decrease in short-term borrowings	-	(50,000)
Repayments of long-term borrowings	(17,404)	(19,658)
Payment of lease liabilities	(121)	-
<b>Net cash flows used in financing activities</b>	<u>(17,525)</u>	<u>(69,658)</u>
<b>Net increase in cash and cash equivalents</b>	104,165	19,573
<b>Cash and cash equivalents at beginning of period</b>	545,980	507,151
<b>Cash and cash equivalents at end of period</b>	<u>\$ 650,145</u>	<u>526,724</u>

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese)

**KENTURN NANO. TEC. CO., LTD.**

**Notes to the Financial Statements**

**March 31, 2024 and 2023**

**(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)**

**(1) Company history**

KENTURN NANO. TEC. CO., LTD. (the “Company”) was established upon the approval of the Ministry of Economic Affairs on December 14, 1983, whose registered address is at No. 16, Zhangbin E. 7th Rd., Xianxi Township, Changhua County 507, Taiwan. The Company mainly engages in mechanical equipment and other machinery manufacturing, as well as international trade and related services.

The Company’s shares were listed on Taipei Exchange in the TPEX since June 11, 2018.

**(2) Approval date and procedures of the financial statements**

The financial statements were authorized for issuance by the board of directors on May 7, 2024.

**(3) New standards, amendments and interpretations adopted**

- (a) The impact of the International Financial Reporting Standards (“IFRS”) endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Company has initially adopted the following new amendments, which do not have a significant impact on its financial statements, from January 1, 2024:

- Amendments to IAS 1 “Classification of Liabilities as Current or Non-current”
- Amendments to IAS 1 “Non-current Liabilities with Covenants”
- Amendments to IAS 7 and IFRS 7 “Supplier Finance Arrangements”
- Amendments to IFRS 16 “Lease Liability in a Sale and Leaseback”

- (b) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Company, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

<b>Standards or Interpretations</b>	<b>Content of amendment</b>	<b>Effective date per IASB</b>
IFRS 18 “Presentation and Disclosure in Financial Statements”	The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.	January 1, 2027

(Continued)



**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

<b>Standards or Interpretations</b>	<b>Content of amendment</b>	<b>Effective date per IASB</b>
IFRS 18 “Presentation and Disclosure in Financial Statements”	<ul style="list-style-type: none"> <li>● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities.</li> <li>● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.</li> <li>● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.</li> </ul>	January 1, 2027

The Company is evaluating the impact on its financial position and financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Company completes its evaluation.

The Company does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IAS21 “Lack of Exchangeability”

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

**(4) Summary of material accounting policies**

**(a) Statement of compliance**

These financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS Accounting Standards endorsed by the FSC) for a complete set of the annual financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the financial statements are the same as those in the financial statement for the year ended December 31, 2023. For the related information, please refer to note 4 of the financial statements for the year ended December 31, 2023.

**(b) Classification of current and non-current assets and liabilities**

The Company classifies the asset as current under one of the following criteria, and all other assets are classified as noncurrent.

- (i) It expects to realize the asset, or intends to sell or consume it, in its normal operating cycle;
- (ii) It holds the asset primarily for the purpose of trading;
- (iii) It expects to realize the asset within twelve months after the reporting period; or
- (iv) The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies the liability as current under one of the following criteria, and all other liabilities are classified as non-current.

- (i) It expects to settle the liability in its normal operating cycle;
- (ii) It holds the liability primarily for the purpose of trading;
- (iii) The liability is due to be settled within twelve months after the reporting period; or
- (iv) It does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(c) **Income taxes**

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management's best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(d) **Employee benefits**

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year adjusted for significant.

(5) **Significant accounting assumptions and judgments, and major sources of estimation uncertainty**

The preparation of the financial statements in conformity with the Regulations and IFRS Accounting Standards (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the financial statements for the year ended December 31, 2023. For related information, please refer to note 5 of the financial statements for the year ended December 31, 2023.

(6) **Explanation of significant accounts**

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the interim financial statements for the current period and the 2023 financial statements. Please refer to note 6 to the 2023 annual financial statements.

(a) **Cash and cash equivalents**

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Pretty cash and cash on hand	\$ 26	14	56
Check deposits	2,435	1,704	4,352
Time deposits	70,892	6,796	6,630
Demand deposits	<u>576,792</u>	<u>537,466</u>	<u>515,686</u>
Cash and cash equivalents in the statement of cash flows	<u>\$ 650,145</u>	<u>545,980</u>	<u>526,724</u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(b) **Financial assets measured at amortized cost**

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Time deposits	\$ <u>19,200</u>	<u>79,833</u>	<u>49,816</u>

The Company has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

For credit risk information, please refer to note 6 (u).

The financial assets at amortized cost had not been pledged as collateral.

(c) **Notes and accounts receivable**

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Notes receivable from operating activities	\$ 3,195	6,474	5,051
Account receivable—measured as amortized cost	162,845	209,341	106,773
Less: Loss allowance	<u>(3,884)</u>	<u>(5,203)</u>	<u>(5,803)</u>
	<u>\$ 162,156</u>	<u>210,612</u>	<u>106,021</u>

The Company applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, accounts receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information, the loss allowance provisions were determined as follows:

	<u>March 31, 2024</u>		
	<u>Gross carrying amount</u>	<u>Weighted- average loss rate</u>	<u>Loss allowance provision</u>
Current	\$ 162,156	-%	-
Past due less than 120 days	-	-%	-
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	<u>3,884</u>	100%	<u>3,884</u>
Total	<u>\$ 166,040</u>		<u>3,884</u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

	<b>December 31, 2023</b>		
	<b>Gross carrying amount</b>	<b>Weighted- average loss rate</b>	<b>Loss allowance provision</b>
Current	\$ 210,612	-%	-
Past due less than 120 days	-	-%	-
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	5,203	100%	5,203
<b>Total</b>	<b>\$ 215,815</b>		<b>5,203</b>
	<b>March 31, 2023</b>		
	<b>Gross carrying amount</b>	<b>Weighted- average loss rate</b>	<b>Loss allowance provision</b>
Current	\$ 106,021	-%	-
Past due less than 120 days	-	-%	-
121 to 240 days past due	-	-%	-
241 to 365 days past due	-	-%	-
More than 1 year past due	5,803	100%	5,803
<b>Total</b>	<b>\$ 111,824</b>		<b>5,803</b>

The movements in the allowance for notes and accounts receivables were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Balance at January 1	\$ 5,203	2,388
Impairment losses recognized	-	3,415
Impairment losses reversed	(1,131)	-
Amounts written off	(188)	-
<b>Balance at March 31</b>	<b>\$ 3,884</b>	<b>5,803</b>

As of March 31, 2024, December 31 and March 31, 2023, the notes and accounts receivables of the Company had not been pledged as collateral.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(d) **Inventories**

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Raw materials	\$ 41,331	24,122	38,615
Work in progress	117,701	86,718	123,684
Semi-finished goods	52,290	59,010	60,768
Finished goods	<u>87,238</u>	<u>82,227</u>	<u>56,964</u>
	<u><b>\$ 298,560</b></u>	<u><b>252,077</b></u>	<u><b>280,031</b></u>

Inventory related losses and profits were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Loss on valuation of inventories	\$ 723	8,112
Revenue from sale of scraps	<u>(520)</u>	<u>(382)</u>
Operating costs	<u><b>\$ 203</b></u>	<u><b>7,730</b></u>

As of March 31, 2024, December 31 and March 31, 2023, the inventories of the Company had not been pledged as collateral.

(e) **Property, plant and equipment**

The cost, depreciation, and impairment of the property, plant and equipment of the Company were as follows:

	<b>Land</b>	<b>Buildings and structures</b>	<b>Machinery and equipment</b>	<b>Transportation equipment</b>	<b>Other equipment</b>	<b>Total</b>
<b>Cost or deemed cost:</b>						
Balance at January 1, 2024	\$ 458,387	721,932	604,120	14,136	17,143	1,815,718
Additions	<u>-</u>	<u>290</u>	<u>1,204</u>	<u>-</u>	<u>188</u>	<u>1,682</u>
Balance at March 31, 2024	<u><b>\$ 458,387</b></u>	<u><b>722,222</b></u>	<u><b>605,324</b></u>	<u><b>14,136</b></u>	<u><b>17,331</b></u>	<u><b>1,817,400</b></u>
Balance at January 1, 2023	\$ 458,387	707,465	731,409	14,633	19,225	1,931,119
Additions	<u>-</u>	<u>172</u>	<u>302</u>	<u>47</u>	<u>863</u>	<u>1,384</u>
Disposal	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,498</u>	<u>-</u>	<u>1,498</u>
Balance at March 31, 2023	<u><b>\$ 458,387</b></u>	<u><b>707,637</b></u>	<u><b>731,711</b></u>	<u><b>16,178</b></u>	<u><b>20,088</b></u>	<u><b>1,934,001</b></u>
<b>Depreciation and impairment loss:</b>						
Balance at January 1, 2024	\$ -	169,463	344,973	9,634	8,784	532,854
Depreciation	<u>-</u>	<u>6,651</u>	<u>9,806</u>	<u>395</u>	<u>745</u>	<u>17,597</u>
Balance at March 31, 2024	<u><b>\$ -</b></u>	<u><b>176,114</b></u>	<u><b>354,779</b></u>	<u><b>10,029</b></u>	<u><b>9,529</b></u>	<u><b>550,451</b></u>
Balance at January 1, 2023	\$ -	143,715	435,979	10,552	13,915	604,161
Depreciation	<u>-</u>	<u>6,265</u>	<u>9,737</u>	<u>468</u>	<u>522</u>	<u>16,992</u>
Balance at March 31, 2023	<u><b>\$ -</b></u>	<u><b>149,980</b></u>	<u><b>445,716</b></u>	<u><b>11,020</b></u>	<u><b>14,437</b></u>	<u><b>621,153</b></u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

	Land	Buildings and structures	Machinery and equipment	Transportation equipment	Other equipment	Total
<b>Carrying amounts:</b>						
Balance at January 1, 2024	\$ 458,387	552,469	259,147	4,502	8,359	1,282,864
Balance at March 31, 2024	\$ 458,387	546,108	250,545	4,107	7,802	1,266,949
Balance at January 1, 2023	\$ 458,387	563,750	295,430	4,081	5,310	1,326,958
Balance at March 31, 2023	\$ 458,387	557,657	285,995	5,158	5,651	1,312,848

As of March 31, 2024, December 31 and March 31, 2023, property, plant and equipment pledged as collateral for long-term borrowings; please refer to note 8.

(f) **Right-of-use assets**

The Company leases other equipment classified as right-of-use assets, the cost and depreciation of right-of-use assets of the Company were as follows:

	Other equipment
<b>Cost:</b>	
Balance at January 1, 2024	\$ 1,200
Additions	1,674
Balance at March 31, 2024	\$ 2,874
<b>Accumulated depreciation:</b>	
Balance at January 1, 2023	\$ 100
Depreciation for the year	143
Balance at March 31, 2024	\$ 243
<b>Carrying amounts:</b>	
Balance at January 1, 2024	\$ 1,100
Balance at March 31, 2024	\$ 2,631
Balance at March 31, 2023	\$ -

(g) **Intangible Assets**

The costs of intangible assets and amortization of the Company were as follows:

	Computer software
<b>Carrying amounts:</b>	
Balance at January 1, 2024	\$ 6,076
Balance at March 31, 2024	\$ 5,613
Balance at January 1, 2023	\$ 16
Balance at March 31, 2023	\$ 6

There were no significant additions, disposal, or recognition and reversal of impairment losses of intangible assets for the three months ended March 31, 2024, and 2023. Information on amortization for the period is discussed in note 12(a). Please refer to note 6(g) to the 2023 annual financial statements for other related information.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(h) **Other current assets and other non-current assets**

The other current assets and other non-current assets of the Company were as follows:

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Other current assets:			
Other financial assets-current	\$ -	-	30,450
Other receivables	4,832	3,229	5,812
Prepayments to suppliers	4,315	719	1,438
Prepaid expenses	<u>1,071</u>	<u>1,122</u>	<u>1,430</u>
	<u>\$ 10,218</u>	<u>5,070</u>	<u>39,130</u>
Other non-current assets:			
Prepayments for equipment	\$ 2,580	-	-
Refundable deposits	<u>10</u>	<u>10</u>	<u>-</u>
	<u>\$ 2,590</u>	<u>10</u>	<u>-</u>

(i) Other financial assets-current is mainly restricted bank deposits as security for bank borrowings, please refer to note 8 for details of the pledge guarantee.

(ii) For credit risk information, please refer to note 6(u).

(i) **Short-term borrowings**

	<u>March 31, 2024</u>	<u>December 31, 2023</u>	<u>March 31, 2023</u>
Secured bank loans	\$ -	-	27,000
Unsecured bank loans	<u>50,000</u>	<u>50,000</u>	<u>98,600</u>
	<u>\$ 50,000</u>	<u>50,000</u>	<u>125,600</u>
Unused short-term credit lines	<u>\$ 100,000</u>	<u>150,000</u>	<u>154,400</u>
Range of internet rates	<u>1.60%</u>	<u>1.60%</u>	<u>1.465%~1.575%</u>

(i) The additional and repayments of borrowings

For the three months ended March 31, 2024, and 2023, the Company had no additional short-term borrowings; and the repayments amounted to \$0 thousand and \$50,000 thousand, respectively. For interest expense, please refer to note 6(t).

(ii) Collateral for short-term borrowing

For the collateral for short-term borrowings, please refer to note 8.

(Continued)



**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(j) **Other payables**

The other payables were summarized as follows:

	<u>March 31,</u> <u>2024</u>	<u>December 31,</u> <u>2023</u>	<u>March 31,</u> <u>2023</u>
Payable on construction and equipment	\$ 1,658	4,103	2,665
Accrued expenses and other	63,140	75,501	48,031
	<u>\$ 64,798</u>	<u>79,604</u>	<u>50,696</u>

(k) **Other current liabilities**

The other current liabilities were summarized as follows:

	<u>March 31,</u> <u>2024</u>	<u>December 31,</u> <u>2023</u>	<u>March 31,</u> <u>2023</u>
Receipts under custody	\$ 2,224	2,057	1,771
Temporary receipts	85	81	138
Deferred revenue	16,008	16,008	-
	<u>\$ 18,317</u>	<u>18,146</u>	<u>1,909</u>

(l) **Long-term borrowings**

The details of long-term borrowings of the Company were as follows:

	<u>March 31,</u> <u>2024</u>	<u>December 31,</u> <u>2023</u>	<u>March 31,</u> <u>2023</u>
Unsecured bank loans	\$ 5,000	7,500	25,048
Secured bank loans	603,813	618,717	663,320
Less: current portion	(64,829)	(67,244)	(78,867)
	<u>\$ 543,984</u>	<u>558,973</u>	<u>609,501</u>
Unused long-term credit line	\$ -	-	-
Range of internet rates	<u>1.79%~2.1285%</u>	<u>1.79%~2.1285%</u>	<u>1.57%~1.9964%</u>

(i) The additional and repayments of borrowings

For the three months ended March 31, 2024 and 2023, the Company had no additional long-term borrowings; and the repayments amounted to \$17,404 thousand and \$19,658 thousand, respectively. For interest expense, please refer to note 6(t).

(ii) The additional and repayments of borrowings

For the collateral for short-term borrowings, please refer to note 8.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(m) **Lease liabilities**

The carrying amount of the Company's lease liabilities were as follows:

	<b>March 31, 2024</b>	<b>December 31, 2023</b>
Current	<u>\$ 949</u>	<u>396</u>
Non-current	<u>\$ 1,527</u>	<u>641</u>

For the maturity analysis, please refer to note 6(u).

The amounts recognized in profit or loss were as follows:

	<b>For the three months ended March 31 2024</b>
Interest on lease liabilities	<u>\$ 10</u>
Expenses relating to short-term leases	<u>\$ 858</u>

The amounts recognized in the statement of cash flows by the Company were as follows:

	<b>For the three months ended March 31 2024</b>
Total cash outflow for leases	<u>\$ 989</u>

(i) Other equipment leases

The Company leases other equipment, with lease terms of three years. The Company has options to purchase the assets at the end of the contract term;

(ii) Other leases

The Company also leases other equipment with contract terms of one year. These leases are short-term and/or leases of low-value items. The Company has elected not to recognize right-of-use assets and lease liabilities for these leases.

(n) **Employee benefits**

(i) Defined benefit plans

There was no material volatility of the market, no material reimbursement and settlement or other material onetime events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2023 and 2022.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

The detail for the Company's expense were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Administration expenses	<b>\$ 38</b>	<b>41</b>

(ii) **Defined contribution plans**

The Company's expenses for the pension plan contributions to the Bureau of Labor Insurance were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Operating cost	\$ 967	830
Selling expenses	134	128
Administration expenses	209	190
Research and development expenses	93	101
Total	<b>\$ 1,403</b>	<b>1,249</b>

(o) **Income Taxes**

(i) **Income taxes**

The components of income tax were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Current tax expense		
Current period	<b>\$ 13,798</b>	<b>3,051</b>

The Company's tax returns for the years through 2021 were assessed and approved by the tax authorized.

(p) **Capital and Other Equity**

- (i) Except for the following disclosure, there was no significant change in capital and other equity for the periods from January 1 to March 31, 2024 and 2023. For the related information, please refer to note 6(p) to the financial statements for the year ended December 31, 2023.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(ii) Retained Earnings

The Company's article of incorporation stipulate that Company's net earnings should first be used to offset the prior years' deficits, if any, before paying any income taxes. Of the remaining balance, 10% is to be appropriated as legal reserve, and then any remaining profit together with any undistributed retained earnings shall be distributed according to the distribution plan proposed by the Board of Directors and submitted to the stockholders' meeting for approval.

The Company's dividend policy is based on the Company's sustainable operation, cost stability, safeguarding the shareholders' rights and interests, and improving the financial structure, wherein the Board of Directors formulates a surplus distribution plan according to the Company's capital needs. If the Company decided to distribute its earnings by cash, the distribution ratio shall not be less than 10% of the total dividends of the shareholders, and has to be decided during the shareholders' meeting. Any adjustment made to the above ratio according to the actual profit and capital situation of the current year shall be proposed by the board during the share shareholders' meeting for approval.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) Earnings distribution

The amount of cash dividends for 2023 earnings distribution had been proposed during the Board of Directors held on March 12, 2024; while the earnings distribution for 2022 had been approved during the Shareholders' Meeting on June 27, 2023 as follows:

	<u>2023</u>		<u>2022</u>	
	<u>Amount per share</u>	<u>Total amount</u>	<u>Amount per share</u>	<u>Total amount</u>
Dividends distributed to common shareholders				
Cash	\$ <u>1.00</u>	<u>58,522</u>	<u>0.70</u>	<u>40,965</u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(q) **Earnings per Share**

The calculation of basic earnings per share and diluted earnings per share were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
<b>Basic earnings per share</b>		
Profit attributable to ordinary shareholders of the Company	\$ <u>55,193</u>	<u>12,203</u>
Weighted average number of outstanding ordinary shares (in thousands)	<u>58,522</u>	<u>58,522</u>
	<u>\$ 0.94</u>	<u>0.21</u>
<b>Diluted earnings per share</b>		
Profit attributable to ordinary shareholders of the Company	\$ <u>55,193</u>	<u>12,203</u>
Weighted average number of ordinary shares (in thousands)	58,522	58,522
Effect of dilutive potential ordinary shares		
Effect of employee shares bonus	<u>493</u>	<u>513</u>
Weightier-average number of ordinary shares (in thousands) (diluted)	<u>59,015</u>	<u>59,035</u>
	<u>\$ 0.94</u>	<u>0.21</u>

(r) **Revenue from contracts with customers**

(i) Details of revenue

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
<u>Primary geographical markets</u>		
China	\$ 168,560	165,873
Taiwan	89,903	61,596
India	16,620	6,480
Other	<u>1,517</u>	<u>518</u>
	<u>\$ 276,600</u>	<u>234,467</u>
<u>Major products/services lines</u>		
Precision spindles and consumables	<u>\$ 276,600</u>	<u>234,467</u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(ii) Contract balances

	<b>March 31, 2024</b>	<b>December 31, 2023</b>	<b>March 31, 2023</b>
Contract liabilities	\$ <b>25,043</b>	<b>36,619</b>	<b>75,185</b>

- 1) Contract liabilities are mainly pre-receipts.
- 2) For details on accounts receivable , notes receivable and allowance for impairment, please refer to note 6 (c).

The amount of revenue recognized for the three months ended March 31, 2024 and 2023 , that was included in the contract liability balance at the beginning of the period were \$12,865 thousand and \$5,511 thousand.

(s) **Employee compensation and directors' remuneration**

In accordance with the articles of incorporation, the Company should contribute not less than 1% and not more than 15% of the profit as employee remuneration. The recipients of shares and cash may include the employees of the Company's subsidiaries who meet certain conditions. The directors shall be entitled to a maximum of 5% of the above amount of profits as their remuneration, with the approval of the board. Both remuneration to employees and directors should be reported during the shareholders' meeting. However, if the Company has accumulated deficits, the profit should be reserved to offset the deficit. In addition, the remuneration of employees and directors shall be allocated in accordance with the proportion set forth in the preceding paragraph.

For the three months ended March 31, 2024 and 2023, the Company estimated its employee remuneration amounting to \$4,025 thousand and \$2,800 thousand, respectively, and directors' remuneration amounting to \$675 thousand and \$500 thousand, respectively. These amounts were calculated using the Company's pre-tax income for each period before deducting the remunerations of employees and directors, multiplied by the proposed percentages of remunerations of employees and directors, as stated in the Company's Articles of Incorporation. These remunerations were expensed under operating costs or expenses for each period. If there are any subsequent adjustments to the actual remuneration amounts after the annual shareholders' meeting, the adjustments will be regarded as changes in accounting estimates and will be reflected in profit or loss in the following year. Shares distributed to employees as remuneration were calculated based on the closing price of the Company's shares on the day before the approval by the Board of Directors.

For the years ended December 31, 2023 and 2022, the Company estimated its employee remuneration amounting to \$16,100 thousand and \$11,200 thousand, respectively, and directors' remuneration amounting to \$2,700 thousand and \$2,000 thousand, respectively. There were no differences to the actual remuneration paid. Related information would be available at the Market Observation Post System website.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(t) **Non-operating Income and Expenses**

(i) Interest income

The details of the interest income were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Interest income from bank deposits	\$ 899	511

(ii) Other income

The details of other income were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Government subsidy	\$ 126	305
Others	11	-
	\$ 137	305

(iii) Other gains and losses

The details of other gains and losses were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Foreign exchange gains	\$ 12,958	2,957

(iv) Finance costs

The details of finance costs were as follows:

	<b>For the three months ended March 31</b>	
	<b>2024</b>	<b>2023</b>
Interest expense - bank loans	\$ 2,994	3,494
Interest expense - lease liabilities	10	-
	\$ 3,004	3,494

(u) **Financial Instruments**

Except for the contention mentioned below, there was no significant change in the fair value of the Company's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For related information, please refer to note 6(u) to the financial statements for the year ended December 31, 2023.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

2) Concentration of credit risk

As of March 31, 2024, December 31 and March 31, 2023, 80%, 86% and 72%, respectively, of trade receivables were five major customers. Thus, credit risk is significantly centralized.

3) Receivables of credit risk

For credit risk exposure of note and trade receivables, please refer to note 6(c).

Other financial assets at amortized cost includes other receivables, time deposits and other financial assets. All of these financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. The Company has no loss allowance provision for the three months ended March 31, 2024 and 2023.

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>With 1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
<b>March 31, 2024</b>						
Non-derivative financial liabilities						
Short-term borrowings	\$ 50,000	50,329	50,329	-	-	-
Notes and accounts payable and other payables	340,739	340,739	340,739	-	-	-
Long-term borrowings (Including due within one year)	608,813	675,464	75,298	69,521	198,387	332,258
Lease liabilities	2,476	2,527	981	981	565	-
	<u>\$ 1,002,028</u>	<u>1,069,059</u>	<u>467,347</u>	<u>70,502</u>	<u>198,952</u>	<u>332,258</u>
<b>December 31, 2023</b>						
Non-derivative financial liabilities						
Short-term borrowings	\$ 50,000	50,132	50,132	-	-	-
Notes and accounts payable and other payables	349,182	349,182	349,182	-	-	-
Long-term borrowings (Including due within one year)	626,217	695,683	78,023	69,705	201,807	346,148
Lease liabilities	1,037	1,059	410	410	239	-
	<u>\$ 1,026,436</u>	<u>1,096,056</u>	<u>477,747</u>	<u>70,115</u>	<u>202,046</u>	<u>346,148</u>
<b>March 31, 2023</b>						
Non-derivative financial liabilities						
Short-term borrowings	\$ 125,600	126,104	126,104	-	-	-
Notes and accounts payable and other payables	233,158	233,158	233,158	-	-	-
Long-term borrowings (Including due within one year)	688,368	761,123	89,807	75,377	204,616	391,323
	<u>\$ 1,047,126</u>	<u>1,120,385</u>	<u>449,069</u>	<u>75,377</u>	<u>204,616</u>	<u>391,323</u>

(Continued)



**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

The Company does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amounts.

(iii) Market risk

1) Currency risk

The Company's significant exposure to foreign currency risk was as follows:

	March 31, 2024			December 31, 2023			March 31, 2023			
	Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD	Foreign currency	Exchange rate	TWD	
<u>Financial assets</u>										
<u>Monetary items</u>										
USD	USD	3,776	32.000	120,832	4,184	30.705	128,470	4.485	30.45	136,568
RMB	RMB	78,018	4.408	343,903	88,737	4.327	383,965	59,317	4.431	262,834

The Company's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, trade receivables that are denominated in foreign currency. A strengthening (weakening) of 1% of the TWD against the foreign currency as of March 31, 2024, December 31 and March 31, 2023 would have increased (decreased) the net profit after tax by \$3,718 thousand and \$3,195 thousand, respectively. The analysis assumes that all other variables remain constant and ignores any impact of forecasted sales and purchases. The analysis is performed on the same basis for prior year.

Since the Company's functional currency is NTD, the exchange gains and losses of its monetary items are accounted for as exchanges in profit or loss (including realized and unrealized), please refer to note 6(t).

2) Interest rate risk

Please refer to the notes on liquidity risk management and interest rate exposure of the Company's financial liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Company management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1 basis points, the Company's net income would have increased / decreased by \$5,271 thousand and \$6,512 thousand for the three months ended March 31, 2024 and 2023, respectively. This is mainly due to the Company's borrowing in variable rates.

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

(iv) Fair value of financial instruments

1) Categories and fair value of financial instruments

The carrying amount and fair value of the Company's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and for equity investments that has no quoted prices in the active markets and whose fair value cannot be reliably measured, disclosure of fair value information is not required:

	<b>March 31, 2024</b>				
	<b>Book value</b>	<b>Fair Value</b>			<b>Total</b>
		<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	
<b>Financial assets measured at amortized cost</b>					
Cash and cash equivalents	\$ 650,145	-	-	-	-
Financial assets measured at amortized cost	19,200	-	-	-	-
Notes receivable, accounts receivable and other receivables	166,988	-	-	-	-
Guarantee deposits	10	-	-	-	-
	<b><u>\$ 836,343</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>
<b>Financial liabilities at amortized cost</b>					
Short-term borrowings	\$ 50,000	-	-	-	-
Notes payable, accounts payable and other payables	340,739	-	-	-	-
Long-term borrowings (Including due within one year)	608,813	-	-	-	-
Lease liabilities	2,476	-	-	-	-
	<b><u>\$ 1,002,028</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>
<b>December 31, 2023</b>					
	<b>Book value</b>	<b>Fair Value</b>			<b>Total</b>
		<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	
<b>Financial assets measured at amortized cost</b>					
Cash and cash equivalents	\$ 545,980	-	-	-	-
Financial assets measured at amortized cost	79,833	-	-	-	-
Notes receivable, accounts receivable and other receivables	213,841	-	-	-	-
Guarantee deposits	10	-	-	-	-
	<b><u>\$ 839,664</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

	<b>December 31, 2023</b>				
	<b>Book value</b>	<b>Fair Value</b>			<b>Total</b>
		<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	
<b>Financial liabilities at amortized cost</b>					
Short-term borrowings	\$ 50,000	-	-	-	-
Notes payable, accounts payable and other payables	347,782	-	-	-	-
Long-term borrowings (Including due within one year)	626,217	-	-	-	-
Lease liabilities	1,037	-	-	-	-
	<b><u>\$ 1,025,036</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>
<b>March 31, 2023</b>					
	<b>Book value</b>	<b>Fair Value</b>			<b>Total</b>
		<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	
<b>Financial assets measured at amortized cost</b>					
Cash and cash equivalents	\$ 526,724	-	-	-	-
Financial assets measured at amortized cost	49,816	-	-	-	-
Notes receivable, accounts receivable and other receivables	111,833	-	-	-	-
Current other financial assets	30,450	-	-	-	-
	<b><u>\$ 718,823</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>
<b>Financial liabilities at amortized cost</b>					
Short-term borrowings	\$ 125,600	-	-	-	-
Notes payable, accounts payable and other payables	233,158	-	-	-	-
Long-term borrowings (Including due within one year)	688,368	-	-	-	-
	<b><u>\$ 1,047,126</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>	<b><u>-</u></b>

2) Valuation techniques for financial instruments not measured at fair value

The Company's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

For financial liabilities measured at amortized cost, if there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimate fair values.

3) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

4) Transfers between Level 1 and Level 2

There were no transfers from Level 1 to another in 2024 and 2023 .

(v) **Financial risk management**

There were no significant changes in the Company's financial risk management and policies as disclosed in note 6(v) to the financial statements for the year ended December 31, 2023.

(w) **Capital management**

Management believes that the objectives, policies and processes of capital management of the Company has been applied consistently with those described in the financial statements for the year ended December 31, 2023. Also, management believes that there were no significant changes in the Company's capital management information as disclosed for the year ended December 31, 2023. Please refer to note 6(w) to the financial statements for the year ended December 31, 2023 for further details.

(x) **Investing and financing activities not affecting current cash flow**

For the Company's investing and financing activities, which did not affect the current cash flow in the three months ended March 31, 2024 and 2023 on its right-of-use assets through lease, please refer to note 6(f).

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

Reconciliation of liabilities arising from financing activities were as follows:

	January 1, 2024	Cash flows	Non-cash changes		March 31, 2024
			Additions/ Reclassification	Fair value movement	
Short-term borrowings	\$ 50,000	-	-	-	50,000
Long-term borrowings (including due within one year)	626,217	(17,404)	-	-	608,813
Lease liabilities	1,037	(121)	1,560	-	2,476
Total liabilities from financing activities	<u>\$ 677,254</u>	<u>(17,525)</u>	<u>1,560</u>	<u>-</u>	<u>661,289</u>
	January 1, 2023	Cash flows	Additions/ Reclassification	Fair value movement	March 31, 2023
Short-term borrowings	\$ 175,600	(50,000)	-	-	125,600
Long-term borrowings (including due within one year)	708,026	(19,658)	-	-	688,368
Total liabilities from financing activities	<u>\$ 883,626</u>	<u>(69,658)</u>	<u>-</u>	<u>-</u>	<u>813,968</u>

**(7) Related-party transactions**

Key management personnel compensation

Key management personnel compensation comprised:

	For the three months ended March 31	
	2024	2023
Short-term employee benefits	\$ 2,292	2,307
Post-employment benefits	-	-
Other long-term benefits	-	-
Termination benefits	-	-
Share-based payments	-	-
	<u>\$ 2,292</u>	<u>2,307</u>

**(8) Pledged assets**

The carrying values of pledged assets were as follows:

Pledged assets	Object	March 31, 2024	December 31, 2023	March 31, 2023
Land	Guarantee for bank loans	\$ 458,387	458,387	458,387
buildings and structures	Guarantee for bank loans	546,108	552,469	557,657
Machinery and equipment	Guarantee for bank loans	183,691	190,331	123,227
Other financial assets-current	Guarantee for bank loans	-	-	30,450
		<u>\$ 1,188,186</u>	<u>1,201,187</u>	<u>1,169,721</u>

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

**(9) Commitments and contingencies**

Unrecognized contractual commitments

	March 31, 2024	December 31, 2023	March 31, 2023
Acquisition of property, plant and equipment	\$ 33,039	34,689	15,401

**(10) Losses due to major disasters:None****(11) Subsequent Events:None****(12) Other**

- (a) A summary of current-period employee benefits, depreciation, and amortization, by function, is as follows:

		For the three months ended March 31						
		2024			2023			
		By item	By function	Cost of Sale	Operating Expense	Total	Cost of Sale	Operating Expense
Employee benefits								
Salary		25,438	17,544	42,982	16,256	15,341	31,597	
Labor and health insurance		2,484	1,174	3,658	2,119	1,090	3,209	
Pension		967	474	1,441	830	460	1,290	
Others		838	920	1,758	556	724	1,280	
Depreciation		14,736	3,004	17,740	14,704	2,288	16,992	
Amortization		8	556	564	-	10	10	

- (b) Seasonality of operationsn

The Company's operations were not affected by seasonality or cyclicity factors.

**(13) Other disclosures**

- (a) Information on significant transactions:None

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Company for the three months ended March 31, 2024:

- (i) Loans to other parties:None
- (ii) Guarantees and endorsements for other parties:None
- (iii) Securities held as of March 31, 2024 (excluding investment in subsidiaries, associates and joint ventures):None

(Continued)

**KENTURN NANO. TEC. CO., LTD.**  
**Notes to the Financial Statements**

- (iv) Individual securities acquired or disposed of with accumulated amount exceeding the lower of NT\$300 million or 20% of the capital stock:None
- (v) Acquisition of individual real estate with amount exceeding the lower of NT\$300 million or 20% of the capital stock:None
- (vi) Disposal of individual real estate with amount exceeding the lower of NT\$300 million or 20% of the capital stock:None
- (vii) Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$300 million or 20% of the capital stock:None
- (viii) Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:None
- (ix) Trading in derivative instruments:None
- (b) Information on investees:None
- (c) Information on investment in Mainland China:None
- (d) Major shareholders:

Shareholder's Name	Shareholding	Shares	Percentage
YEH TSAI, HSIU-HUA		7,707,879	13.17 %
SHIDAMA O Investment Co., Ltd.		7,058,000	12.06 %
HENG-TSAN, YEN		5,838,728	9.97 %
BEIZI Investment Co., Ltd.		3,588,804	6.13 %
RONGWEN Investment Co., Ltd.		3,551,979	6.06 %

**(14) Segment information**

The reportable information of segment's profit and assets is in accordance with the financial statements. Please refer to Statements of Financial Position and Statements of Comprehensive Income.